Background: High altitude is a challenging condition caused by insufficient oxygen supply. Inability to adjust to hypoxia may lead to pulmonary edema, stroke, cardiovascular dysfunction, and even death. Thus, understanding the molecular basis of adaptation to high altitude may reveal novel therapeutics to counteract the detrimental consequences of hypoxia.
h ypoxia is defined as inadequate O 2 supply to the whole body or a region of the body. Hypoxia is commonly seen in patients with cardiovascular, 1-3 respiratory, 4, 5 and hemolytic 6 diseases. Hypoxic conditions associated with these diseases are dangerous because decreased O 2 availability promotes end-organ damage and failure. Hypoxia also frequently occurs in healthy individuals when they travel to high altitude or other low-O 2 -content environments. 7, 8 It is widely observed that people differ in their ability to adapt to high-altitude hypoxia. [8] [9] [10] [11] Inability to adapt quickly to altitude hypoxia can result in pulmonary edema, stroke, cardiovascular dysfunction, and even death. 3, 7, 12, 13 Thus, hypoxia is a highly dangerous condition for both normal individuals exposed to high-altitude hypoxia and patients with cardiovascular, respiratory, and hemolytic diseases. However, current strategies to counteract hypoxia are limited by a lack of fundamental understanding of molecular mechanisms underlying adaptation to hypoxia.
The erythrocyte, the most abundant circulating cell type, is responsible for delivery of O 2 to peripheral tissues. To function effectively in O 2 uptake, transport, and delivery, especially under hypoxic conditions, erythrocytes rely on sophisticated regulation of hemoglobin-O 2 affinity by endogenous allosteric modulators. One of the best-known allosteric modulators is 2,3-bisphosphoglycerate (2,3-BPG), a metabolic byproduct of glycolysis synthesized primarily in erythrocytes for the purpose of regulating hemoglobin-O 2 affinity. 14 It has been known for >4 decades that when humans ascend to high altitude the concentration of 2,3-BPG in erythrocytes increases significantly, and its elevation is associated with an increased capacity of O 2 release from hemoglobin. 15 Erythrocyte 2,3-BPG levels are also elevated in many cardiovascular diseases associated with hypoxia. [16] [17] [18] However, the molecular basis underlying high altitude and disease-related hypoxia-induced erythrocyte 2,3-BPG remains unknown.
To address these questions, we recruited 21 young healthy human volunteers and conducted high-altitude studies. Our human studies showed that circulating adenosine levels and the activity of soluble ecto-5'-nucleotidase (CD73), a key enzyme to generate extracellular adenosine, were significantly induced at high altitude and were associated with increased erythrocyte 2,3-BPG and O 2 releasing capacity. In vivo genetic mouse studies coupled with in vitro human and mouse studies demonstrated that increased extracellular adenosine signaling via the erythrocyte A2B adenosine receptor (ADORA2B) led to the sequential activation of AMP-activated protein kinase (AMPK; a well-known cellular energy sensor) and 2,3-BPG mutase, resulting in increased 2,3-BPG production and enhanced O 2 release capacity to peripheral tissues and in turn reduced tissue hypoxia, inflammation, and pulmonary injury. Thus, our findings highlight the importance of this newly identified erythrocyte adenosine signaling pathway via AMPK in human adaptation to high altitude and identify several attractive targets to counteract hypoxia in humans.
MethOds
For expanded Methods sections, please refer to the online-only Data Supplement.
human subjects
This study was conducted as part of the AltitudeOmics project examining the integrative physiology of human responses to hypoxia. 19 In brief, all procedures conformed to the Declaration of Helsinki and were approved by the Institutional Review Boards at the University of Colorado and University of Oregon and the US Department of Defense Human Research Protection Office. After providing informed written consent, recreationally active sea level (SL) habitants participated in the high-altitude study. The participants were nonsmokers, were free from cardiorespiratory disease, were born and raised at <1500 m, and had not traveled to elevations >1000 m in the 3 months before the investigation.
Each subject was studied near SL (130 m; average barometric pressure=749 mm Hg) and on the 1st (ALT1) and 16th (ALT16) days at Mt. Chacaltaya 
Mouse subjects
Eight-to 10-week-old C57BL/6 wild-type (WT) mice were purchased from Harlan Laboratories (Indianapolis, IN). CD73deficient (Cd73 −/− ) mice and A1, A2A, A2B, and A3 adenosine receptor (ADORA1, ADORA2A, ADORA2B, and ADORA3) -deficient mice with C57BL/6 background were generated and genotyped as described previously. 20, 21 A novel line of mice with erythrocyte-specific deletion of Adora2b was generated by crossing mice homozygous for a floxed Adora2b allele with mice expressing Cre recombinase under the control of erythropoietin receptor (EpoR) gene regulatory elements. 22 All protocols involving animal studies were reviewed and approved by the Institutional Animal Welfare Committee of the University of Texas Health Science Center at Houston.
Blood collection and Preparation
Human and mouse blood were collected and stored as described earlier. 20, 23 Approximately 4 mL human blood was collected with heparin as an anticoagulant for 2,3-BPG measurement with a commercial assay (Roche, USA) as previously described. 20 For plasma adenosine assay, 1 mL EDTA-collected blood was divided into aliquots in tubes containing 10 μmol/L dipyridamole (an inhibitor of equilibrative nucleoside transporters) and 10 μmol/L deoxycoformycin (an inhibitor of adenosine deaminase). Approximately 1 mL mouse blood was collected and used for 2,3-BPG and plasma adenosine measurement, similar to human blood described above. 20, 23 High-altitude human blood was collected and stored at −80°C after collection and during shipment from the field until assay.
Measurement of soluble cd73 activity in lowland Volunteers
Soluble CD73 (sCD73) enzyme activity in humans was measured by quantifying the rate of conversion of [ 3 H]-AMP to [ 3 H]-adenosine as described previously. 24, 25 Briefly, sCD73 activity was measured after incubation of plasma with 300 μmol/L [ 3 H]AMP (Quotient Bioresearch; GE Healthcare, Rushden, UK) for 60 minutes at 37°C. Premixture was then applied onto Alugram SIL G/UV254 sheets (Macherey-Nagel, Germany). Radiolabeled substrates and their products were separated by thin-layer chromatography and quantified by scintillation β-counting.
Plasma adenosine Measurement
Plasma adenosine concentration was measured by reversephase high-performance liquid chromatography as previously described. 20 Briefly, 500 μL plasma was used to isolate adenosine by sequentially adding 0.6 mol/L cold perchloric acid, 3 mol/L KHCO 3 /3.6N KOH, 1.8 mol/L ammonium dihydrogen phosphate (pH 5.1), and phosphoric acid (30%). Next, the sample was centrifuged at 20 000g for 5 minutes, and the supernatant was transferred to a new tube for reversephase high-performance liquid chromatography analysis. Adenosine content was normalized to volume and expressed as a concentration.
Measurement of P50 in lowland Volunteers
Arterial bloods of high-altitude human subjects were collected and used for P50 measurement. Blood Pao 2 and pH were measured by blood gas analyzer, and Sao 2 was measured by Co-Oximeter. P50 was then calculated by use of a Hill constant of 2.7 and the standard equation as described previously. 26 statistics All data are expressed as mean±SEM. Data were analyzed for statistical significance with GraphPad Prism 5 software. Nonparametric-equivalent Wilcoxon rank-sum tests were applied in 2-group analysis. Differences between the means of multiple groups were compared by 1-way ANOVA, followed by a Tukey multiple-comparisons test. Comparison of the data obtained at different time points was analyzed by 2-way repeated measures, followed by the Tukey post hoc test. A value of P< 0.05 was considered significant.
results Metabolomic screening reveals that highaltitude hypoxia activates the rapoportluebering shunt in erythrocytes, resulting in increased Production of 2,3-BPg and elevated Oxygen release From hemoglobin
To identify metabolic alterations in erythrocytes in response to hypoxia, we conducted nonbiased, highthroughput metabolomic profiling of erythrocytes from humans at SL and at high altitude. Specifically, we recruited 21 young healthy lowland volunteers who were examined at SL and within 2 hours of arrival at an altitude of ≈5260 m (ALT1) and on day 16 at high altitude (ALT16; Figure 1A ). Overall, 233 metabolites were confidently identified and relatively quantified of >9000 detected features (mass-to-charge ratios) in erythrocytes under SL conditions and at high altitude ( Table I in the online-only Data Supplement). Analysis of these metabolic changes revealed that the erythrocyte-specific Rapoport-Luebering shunt, occurring at a branch point in the pathway of glycolysis for production of 2,3-BPG from 1,3-bisphoglycerate ( Figure 1B) , was rapidly activated by high-altitude hypoxia. Specifically, levels of BPG and its upstream glycolytic intermediate, glyceraldehyde-3-phosphate, were increased at ALT1 and were further elevated at ALT16 (Fig-Figure 1 . Metabolomic profiling reveals that high-altitude hypoxia increases erythrocyte-specific rapoportluebering shunt to induce 2,3-bisphophoglycerate (2,3-BPg) production and P50 levels in humans. a, Table of human volunteer characteristics, including age, height (HT), weight (WT), body mass index (BMI), and schema for high-altitude human studies (n=21). B, Schematic drawing of erythrocyte-specific Rapoport-Luebering shunt occurring at a branch point in the pathway of anaerobic glycolysis for 2,3-BPG production. c through F, Metabolomic profiling reveals the significant changes in the relative erythrocyte concentration of glyceraldehyde-3-phosphate (G3P; c), bisphosphoglycerate (BPG; d), the monophosphoglycerates 2-phosphoglycerate (2-PG) and 3-phosphoglycerate (3-PG; e), and phosphoenolpyruvate (PEP; F) at sea level (SL) and at high altitude on day 1 (ALT1) and day 16 (ALT16). g through J, Erythrocyte 2,3-BPG concentration, P50 level, plasma adenosine concentration, and soluble CD73 activity (sCD73) were elevated at high-altitude hypoxia on ALT1 and ALT16 over SL. Erythrocyte 2,3-BPG concentration (g), P50 level (h), plasma adenosine concentration (i), and sCD73 (J). Data are expressed as mean±SEM. AU indicates area under the peak. *P<0.05 vs SL; **P<0.05 vs ALT1. ure 1C and 1D). In contrast, the levels of the erythrocyte monophosphoglycerates (3-PG and 2-PG) and phosphoenolpyruvate, the 3 immediate downstream products of 2,3-BPG, were significantly reduced at ALT1 and further reduced at ALT16 compared with SL ( Figure 1E and 1F). To validate our metabolomic screening, we quantified erythrocyte 2,3-BPG concentrations in human samples. Consistently, we found that the erythrocyte 2,3-BPG concentration was significantly induced at ALT1 and further elevated at ALT16 ( Figure 1G ). Thus, our results indicate that in response to high-altitude hypoxia the Rapoport-Luebering Shunt is activated, resulting in a significant portion of glyceraldehyde-3-phosphate being used to produce 2,3-BPG rather than directly being metabolized to the glycolytic intermediate, 3-PG ( Figure 1B ). Because 2,3-BPG is an allosteric modulator that decreases hemoglobin-O 2 binding affinity and thereby promotes O 2 release, 14 it is possible that hypoxia-induced 2,3-BPG production in erythrocytes triggers O 2 release. To test this possibility, we quantified the O 2 release capacity of erythrocytes by measuring P50, the partial pressure of O 2 required to achieve 50% hemoglobin-O 2 saturation, from the human subjects at high altitude. We found that erythrocyte P50 was significantly induced at ALT16 compared with ALT1, reflecting reduced hemoglobin-O 2 binding affinity and enhanced erythrocyte O 2 release capacity at high altitude ( Figure 1H ). No significant differences were noted between male and female subjects ( Figure IA and IB in the online-only Data Supplement). These findings provide evidence that high-altitude hypoxia coordinately induces erythrocyte 2,3-BPG production and P50 levels in humans adapting to high altitude ( Figure 1B ).
extracellular adenosine concentrations and scd73 activity increase in humans at high altitude
Specific factors and signaling pathways involved in 2,3-BPG induction and subsequent O 2 release from erythrocytes under high altitude have not been previously identified. Recent studies show that increased circulating adenosine is involved in 2,3-BPG induction in erythrocytes of individuals with sickle cell disease. 20 However, whether adenosine signaling contributes to normal erythrocyte 2,3-BPG induction and subsequent O 2 release underlying high-altitude hypoxia adaptation remains unknown. To test this hypothesis, we used highperformance liquid chromatography to measure plasma adenosine levels in the 21 lowland volunteers at SL and after ascent to high altitude. We found that the circulating adenosine levels were elevated at ALT1 compared with SL and were further elevated at ALT16 ( Figure 1I ). No significant differences in elevated plasma adenosine levels were observed between male and female participants ( Figure IC in the online-only Data Supplement).
CD73 is an ectoenzyme anchored to the cell surface that plays a key role in the synthesis of extracellular adenosine from AMP. 27 Under certain circumstances, the ectoenzyme can be cleaved from the cell surface and can emerge in the circulation as a soluble nucleotidase. 28 Therefore, we measured sCD73 activity in normal individuals at SL and at high altitude. sCD73 activity was significantly increased in the human subjects at ALT1 compared with SL and further increased at ALT16 ( Figure 1J ). There were no significant differences in elevated sCD73 activity between male and female participants in response to high-altitude hypoxia ( Figure ID in the online-only Data Supplement). Taken together, these results show that plasma adenosine concentration and sCD73 activity increase rapidly in response to high-altitude hypoxia and that their induction is associated with increased erythrocyte 2,3-BPG concentrations and P50 levels. scd73 activity is induced by hypoxia and elevated cd73 is essential for hypoxia-induced Plasma adenosine, erythrocyte 2,3-BPg, and O 2 release capacity Although extracellular adenosine is well known to orchestrate a physiological response to tissue injury, 29 nothing is known about the functional role of adenosine signaling in normal erythrocytes under hypoxia. Our human studies presented above raise an intriguing hypothesis that activated CD73-mediated elevated plasma adenosine has a previously unrecognized role in high-altitude adaption by regulating 2,3-BPG production and hemoglobin-O 2 binding affinity in erythrocytes. To test this hypothesis, we exposed WT mice and Cd73 −/− mice to normobaric hypoxia (10% oxygen, similar to that at 5260 m) for 1 week. Similar to the human high-altitude studies, we found that CD73 activity, plasma adenosine, erythrocyte 2,3-BPG, and O 2 releasing capacity were significantly increased in WT mice after 1 week of hypoxia compared with normoxia (Figure 2A-2D ). In contrast, hypoxia-mediated increased plasma adenosine, erythrocyte 2,3-BPG, and O 2 releasing capacity were significantly impaired in Cd73 −/− mice (Figure 2A-2D) . These results indicate that in mice CD73 activity is induced by hypoxia, as seen in human volunteers at high altitude, and that CD73 is required for hypoxia-induced plasma adenosine production and elevated erythrocyte 2,3-BPG concentration and O 2 release capacity.
cd73-Mediated elevated Plasma adenosine Prevents tissue hypoxia, inflammation, and lung injury in Mice
To assess the functional importance of CD73-mediated increased plasma adenosine in tissue response to hypoxia, we measured tissue hypoxia levels using an immunohistochemical analysis with hypoxyprobe in WT mice and Cd73 -/mice under normoxia and after 1 week of hypoxia as described above. No hypoxia signals were seen in tissue sections of Cd73 -/or WT mice under normoxia ( Figure 2E ). However, under hypoxia, hypoxyprobe revealed that multiple organs, including kidneys, lungs, and hearts, displayed a mild hypoxia signal in WT mice ( Figure 2E ). In contrast, 1 week of 10% O 2 led to severe hypoxia in various organs, including kidneys, lungs, and hearts, of Cd73 -/mice (Figure 2E) . Image quantification analysis demonstrated that the intensity of hypoxyprobe in the kidneys, lungs, and hearts was significantly elevated in Cd73 -/mice compared with WT mice (Figure IIB-IID in the onlineonly Data Supplement).
Besides analyzing tissue hypoxia, we further quantified neutrophils in multiple tissues because it has been reported that hypoxia rapidly induces infiltration of neutrophils to tissue. 30, 31 Specifically, we measured the activity of myeloperoxidase, a specific enzyme expressed in neutrophils, in multiple tissues under normoxia and hypoxia in WT and Cd73 -/mice. Similar to tissue hypoxia staining ( Figure 2E ), we found that myeloperoxidase activity was mildly induced by hypoxia in multiple tissues of WT mice and was significantly induced further by hypoxia in multiple tissues of Cd73 -/mice compared with WT mice ( Figure 2F ). Thus, we conclude that CD73-mediated elevation of plasma adenosine is beneficial in preventing tissue hypoxia and inflammation.
Hypoxia is known to induce lung injury, including pulmonary vascular leakage and inflammation. 19 Thus, we collected bronchoalveolar lavage fluid (BALF) of WT and Cd73 -/mice for evaluation of pulmonary damage and inflammation. Specifically, we quantified cell count, albumin concentration, and interleukin-6 concentration in BALF of WT and Cd73 -/mice under normoxia and hypoxia. Consistent with our tissue hypoxia staining and myeloperoxidase activity measurements in the lung (Figure 2E and 2F), cell count and albumin and interleukin-6 concentrations in BALF were slightly induced by hypoxia in WT mice, and their levels were significantly further increased in Cd73 -/mice (Figure 2G-2I ). Thus, these results show that CD73-mediated elevation of plasma adenosine plays a beneficial role in preventing hypoxia-induced lung damage and inflammation in mice.
adOra2B underlies hypoxia-induced 2,3-BPg Production and O 2 release capacity in in Vitro cultured Mouse erythrocytes It is known that increased extracellular adenosine elicits physiological or pathological functions by engaging its 4 adenosine receptors: ADORA1, ADORA2A, ADOR-A2B, and ADORA3. 32 Each adenosine receptor has a distinct cellular or tissue distribution and affinity for adenosine. 33 To identify which adenosine receptor is responsible for hypoxia-induced 2,3-BPG production and O 2 release capacity in erythrocytes, we conducted genetic studies in 4 adenosine receptor-deficient mice. We found that hypoxia significantly induced 2,3-BPG production and O 2 release capacity in cultured erythrocytes isolated from WT mice, Adora1-deficient mice, Adora2a-deficient mice, and Adora3-deficient mice. However, hypoxia-mediated effects were absent in cultured erythrocytes isolated from Adora2b-deficient mice ( Figure 3A and 3B) , indicating that hypoxia-induced erythrocyte 2,3-BPG production and O 2 release capacity are dependent on ADORA2B.
genetic deletion of erythrocyte adOra2B attenuates hypoxia-induced 2,3-BPg Production and O 2 release capacity in Vivo
To precisely determine the importance of erythrocyte ADORA2B-mediated elevated 2,3-BPG production and O 2 release in hypoxia, we generated mice with erythrocyte lineage-specific ablation of Adora2b genes by mating mice with floxed Adora2b alleles (Adora2b f/f ) with mice containing a transgene expressing Cre recombinase only in the erythroid lineage (EpoR-Cre + ; Figure IIIA in the online-only Data Supplement). First, we validated the specificity and efficiency of ablation of Adora2b in erythroid cells by EpoR-Cre using bone marrow cells isolated from Epo-Cre + , Adora2b f/f /EpoR-Cre + , and Adora2b −/− mice. The bone marrow-derived hematopoietic progenitor cells were enriched by negative selection, followed by induction to erythroid progenitor cells in erythroid-differentiation medium containing erythropoietin ( Figure IIIB in the online-only Data Supplement). After 2 days, we found that >96% of harvested hematopoietic progenitor cells isolated and enriched from Epo-Cre + , Adora2b f/f /EpoR-Cre + , and Adora2b −/− mice were differentiated into CD71 + erythroid progenitor cells, which is consistent with a previous publication ( Figure IIIC in the online-only Data Supplement). 34 Moreover, quantitative reverse transcription-polymerase chain reaction analysis showed that erythrocyte lineage Adora2b mRNA levels of Adora2b f/f /EpoR-Cre + were reduced to levels similar to that of Adora2b −/− mice, whereas pulmonary Adora2b mRNA levels in Adora2b f/f / EpoR-Cre + were still similar to levels in control mice (EpoR-Cre + ; Figure IIID and IIIE in the online-only Data Supplement). These results demonstrated that we had successfully generated mice with erythrocyte lineagespecific deletion of Adora2b.
To test the functional role of erythrocyte ADORA2B signaling in response to hypoxia, we exposed EpoR- Cre mice and Adora2b f/f /EpoR-Cre + mice to normoxia or hypoxia (10% O 2 ) for 1 week. The levels of plasma adenosine, erythrocyte 2,3-BPG, and P50 were similar in EpoR-Cre + mice and Adora2b f/f /EpoR-Cre + mice under normoxia ( Figure 3C-3E ). After 1 week of hypoxia exposure, plasma adenosine concentrations increased to similar levels in EpoR-Cre + mice and Adora2b f/f /EpoR-Cre + mice ( Figure 3C ). However, the hypoxia-induced erythrocyte 2,3-BPG production and P50 levels observed in the EpoR-Cre + mice were significantly attenuated in Adora2b f/f /EpoR-Cre + mice ( Figure 3D and 3E) . Thus, our studies provide strong genetic evidence that mouse erythrocyte ADORA2B is essential for elevated adenosine-mediated induction of erythrocyte 2,3-BPG and O 2 releasing capacity under hypoxia. erythrocyte adOra2B is essential to Protect against tissue hypoxia, inflammation, and lung damage To further determine whether erythrocyte ADORA2B signaling is tissue protective under hypoxia, we assessed tissue hypoxia by hypoxyprobe in EpoR-Cre + mice and Adora2b f/f /EpoR-Cre + mice after 1 week of hypoxia (10% O 2 ). We found that hypoxia treatment led to severe tissue hypoxia in various organs, including kidneys, lungs, and hearts, in Adora2b f/f /EpoR-Cre + mice, whereas only a mild hypoxia signal was present in those tissues of EpoR-Cre + mice ( Figure 3F ). Image quantification analysis demonstrated that the intensity of hypoxyprobe signals in kidneys, lungs, and hearts was significantly elevated in Adora2b f/f /EpoR-Cre + mice compared with EpoR-Cre + mice (Figure IVB-IVD in the online-only Data Supplement) after hypoxia challenge. We also observed a greater elevation of myeloperoxidase activity in kidney, lung, and heart of Adora2b f/f / EpoR-Cre + mice compared with EpoR-Cre + mice after hypoxia exposure ( Figure 3F ). Furthermore, greater lung injury reflected by increased cell counts and albumin and interleukin-6 concentrations in BALF was detected in Adora2b f/f /EpoR-Cre + mice after hypoxia challenge ( Figure 3H-3J ). These findings demonstrate that erythrocyte ADORA2B is essential for tissue protection during hypoxia exposure.
aMPK Functions downstream of erythrocyte adOra2B in Mice and underlies hypoxiainduced 2,3-BPg Production by Phosphorylation and activation of 2,3-BPg Mutase Erythrocyte 2,3-BPG is synthesized from the glycolytic intermediate 1,3-bisphoglycerate by 2,3-BPG mutase ( Figure 1B) . Factors regulating 2,3-BPG production are poorly understood. A previous report identified that 2,3-BPG mutase is one of the substrates of AMPK in erythrocytes, and follow-up studies validated that purified AMPK directly phosphorylates purified 2,3-BPG mutase in a cell free system. 35 Additional studies showed that ADORA2B signaling activates AMPK in other cellular systems. 36 Like adenosine, AMPK plays an essential role in multiple cellular functions especially under conditions of energy depletion or limited O 2 availability. 37 However, whether AMPK functions downstream of ADORA2B as a key enzyme responsible for hypoxia-induced 2,3-BPG production in erythrocytes has not been previously studied. To test this possibility, we exposed EpoR-Cre mice and Adora2b f/f /EpoR-Cre + mice to hypoxia (10% oxygen) for different times. We found that erythrocyte phosphorylate (p-)AMPK, 2,3-BPG mutase activity, 2,3-BPG concentration, and P50 level were significantly induced in EpoR-Cre mice under hypoxia in a time-dependent manner. However, hypoxia-induced time-dependent elevation of p-AMPK, 2,3-BPG mutase activity, 2,3-BPG, and P50 were significantly attenuated in Adora2b f/f /EpoR-Cre + mice ( Figure 4A-4D ). Next, we conducted experiments to determine whether hypoxia activated AMPK interacts with and phosphorylates 2,3-BPG mutase in erythrocytes. Specifically, we assessed AMPK activation by monitoring its phosphorylation at T172 of the catalytic α subunit in erythrocytes. We found that basal erythrocyte p-AMPKα at T172 levels were similar in Adora2b f/f /EpoR-Cre + mice and EpoR-Cre + mice under normoxia ( Figure 4E ), whereas p-AMPKα at T172 was significantly induced in erythrocytes of EpoR-Cre + mice after 1 week of hypoxia (10% O 2 ) . In contrast, hypoxia-induced p-AMPKα at T172 was significantly attenuated in the erythrocytes of Adora2b f/f / EpoR-Cre + mice ( Figure 4E ). Then, using an antibody that recognizes p-AMPK substrates, we showed that p-AMPK specifically phosphorylates 2,3-BPG mutase and that under normoxia the levels of AMPK-phosphorylated 2,3-BPG mutase were similar in Adora2b f/f /EpoR-Cre + mice and EpoR-Cre + mice ( Figure 4F ). Subsequently, we found that hypoxia significantly induced p-AMPK-phosphorylated 2,3-BPG mutase in erythrocytes of EpoR-Cre + mice and that this phosphorylation was significantly attenuated in Adora2b f/f /EpoR-Cre + mice ( Figure 4F) .
Finally, to determine the essential role of AMPK activation in adenosine ADORA2B-mediated induction of 2,3-BPG, P50, and subsequent tissue protection, we treated Cd73 −/− and Adora2b f/f /EpoR-Cre + mice with AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), a cell-permeable AMPK activator. 38 Specifically, we treated these mice with AICAR under hypoxia (10% O 2 ) for 3 days. Our results ( Figure 4G-4J) show that AICAR treatment restored erythrocyte AMPK phosphorylation, 2,3-BPG mutase activity, 2,3-BPG, and P50 in both Cd73 −/− and Adora2b f/f /EpoR-Cre + mice under hypoxia. Thus, our results demonstrate that AICAR can override a genetic block to hypoxia-induced adenosine production (CD73 ORIGINAL RESEARCH ARTICLE 415 deficiency) or erythrocyte ADORA2B signaling (erythrocyte-specific ADORA2B deficiency) to stimulate erythrocyte 2,3-BPG production and O 2 release capacity by the pharmacological activation of AMPK. Taken together, these findings provide in vivo evidence that AMPK is a critical intermediate that functions downstream of erythrocyte ADORA2B underlying hypoxia-induced 2,3-BPG production by phosphorylation and activation of 2,3-BPG mutase.
aMPK activation induces erythrocyte 2,3-BPg Mutase activity, 2,3-BPg Production, and Oxygen release capacity in Mice under normoxia Our discovery that erythrocyte AMPK is activated and subsequently phosphorylates 2,3-BPG mutase in response to adenosine ADORA2B signaling suggests that activation of AMPK may be sufficient to induce 2,3-BPG production by activating 2,3-BPG mutase. To test this possibility, we conducted in vitro studies in cultured WT mouse erythrocytes with AICAR. Initially, we found that AICAR treatment significantly induced phosphorylation of AMPK and activity of 2,3-BPG mutase, 2,3-BPG levels, and P50 in a time-dependent manner ( Figure VA -VD in the online-only Data Supplement). To further test whether AICAR-mediated effects in cultured erythrocytes were dependent on AMPK, we used Compound C (dorsomorphin), a cell-permeable inhibitor of AMPK. [38] [39] [40] Our results showed that Compound C cotreatment significantly attenuated AICAR-induced p-AMPK, 2,3-BPG mutase activity, 2,3-BPG, and O 2 releasing capacity in cultured mouse erythrocytes ( Figure VA -VD in the online-only Data Supplement). Thus, our in vitro studies demonstrated that AMPK activation is sufficient to induce 2,3-BPG production and enhanced O 2 release capacity in mouse erythrocytes.
Next, we extended in vitro studies to in vivo to test whether AICAR treatment in WT mice under normoxia is capable of inducing AMPK, 2,3-BPG mutase activity, and 2,3-BPG production. As expected, we found that AICAR treatment directly induced phosphorylation of AMPK, 2,3-BPG mutase activity, 2,3-BPG production, and P50 levels in WT mice under normoxia ( Figure VE -VH in the online-only Data Supplement).
in Vivo Beneficial effects of aMPK activation in hypoxia adaptation in Mice
To determine the in vivo effect of AMPK activation in hypoxia adaptation in WT mice, we pretreated WT mouse with AICAR before a hypoxic challenge. For these experiments, a lower O 2 content (8% O 2 ) was used for a shorter period of hypoxia exposure up to 24 hours for evaluating the therapeutic potential of AMPK activation in WT mice. We found that AICAR treatment induced a greater eleva-tion of erythrocyte 2,3-BPG and O 2 releasing capacity by further stimulating erythrocyte p-AMPK and 2,3-BPG mutase activity in WT mice compared with the salinetreated group under hypoxia ( Figure 5A-5D ). Immunohistochemical analysis with hypoxyprobe and myeloperoxidase activity measurement showed that AICAR treatment significantly attenuated tissue hypoxia and inflammation in lung, kidney, and heart in WT mice compared with the saline-treated group under hypoxia ( Figure 5E-5H and Figure VIA -VIC in the online-only Data Supplement).
Next, to validate that AMPK activation is essential for hypoxia adaptation, we treated WT mice with Compound C under hypoxia. We found that Compound C treatment significantly suppressed hypoxia-induced p-AMPK, 2,3-BPG mutase activity, 2,3-BPG production, and O 2 releasing capacity in WT mouse erythrocytes, thereby resulting in enhanced tissue hypoxia and inflammation in lungs, kidneys, and hearts compared with the saline-treated group under hypoxia ( Figure 5E-5H and Figure VIA -VIC in the online-only Data Supplement). These studies indicate that erythrocyte p-AMPK is critical for enhanced hypoxia adaptation in WT mice by rapidly inducing 2,3-BPG mutase activity, 2,3-BPG levels, and subsequent O 2 release to peripheral tissues. erythrocyte p-aMPK and 2,3-BPg Mutase activity are induced in humans at high altitude, and aMPK activation induces erythrocyte 2,3-BPg Mutase activity, 2,3-BPg Production, and Oxygen release in cultured human erythrocytes To translate our mouse findings to humans, we measured erythrocyte p-AMPK by Western blot and ELISAs in human subjects at SL and at high altitude on ALT1 and ALT16. We found that erythrocyte p-AMPK levels were increased at ALT1 and were further elevated at ALT16 ( Figure 6A and 6B). No significant differences in p-AMPK levels were observed between male and female volunteers in response to high altitude ( Figure IE in the online-only Data Supplement). Additionally, we found that erythrocyte 2,3-BPG mutase activity was induced at ALT1 and was further elevated at ALT16 ( Figure 6C) . Consistently, we observed that levels of p-AMPK-phosphorylated 2,3-BPG mutase in erythrocytes were significantly increased at ALT1 and were further enhanced at ALT16 ( Figure 6D ), implicating that AMPK activation is associated with high-altitude hypoxia-induced activation of erythrocyte 2,3-BPG mutase in humans.
To translate our mouse findings on the significance of AMPK activation in erythrocytes to humans, we conducted a series of in vitro studies by culturing normal human erythrocytes. First, we found that AICAR treatment induced p-AMPK, 2,3-BPG mutase activity, 2,3-BPG levels, and subsequent O 2 release in cultured normal human erythrocytes in a time-dependent manner ( Figure 6E-6H ). To further test whether AICAR- mediated effects in cultured human erythrocytes are dependent on AMPK, we incubated AICAR-treated human normal erythrocytes with or without Compound C. We found that Compound C significantly attenuated AICAR-induced p-AMPK and 2,3-BPG mutase activity, 2,3-BPG levels, and O 2 release capacity in cultured human erythrocytes ( Figure 6E-6H ). Taken together, these data show that high-altitude hypoxia induces human erythrocyte p-AMPK and 2,3-BPG mutase activity in a time-dependent manner. In vitro experiments with cultured human erythrocytes showed that activation of AMPK induces 2,3-BPG mutase activity, 2,3-BPG production, and subsequent O 2 release in cultured human erythrocytes. Compound C inhibits AMPK activation and subsequently suppresses the induction of 2,3-BPG mutase activity, 2,3-BPG production, and O 2 release in cultured human erythrocytes. Thus, we provide human evidence that AMPK activation triggers erythrocyte O 2 release by promoting 2,3-BPG mutase activity and 2,3-BPG production.
discussiOn
It has been known for >4 decades that when humans ascend to high altitudes the affinity of hemoglobin for O 2 decreases to make more O 2 available to hypoxic peripheral tissues. 15, 41 It was also recognized early that the reduced O 2 affinity was due in part to the increase in erythrocyte 2,3-BPG, which functioned as a negative allosteric regulator of hemoglobin-O 2 affinity. 14, 42, 43 The molecular mechanisms accounting for the high altitude-mediated regulation of erythrocyte 2,3-BPG concentration were not understood until we conducted nonbiased metabolomic screening of erythrocytes in humans and mouse genetic studies. Both human and mouse studies reported here provide strong evidence that CD73-mediated adenosine signaling via ADORA2B in erythrocytes plays a beneficial role in preventing hypoxia-induced tissue hypoxia, inflammation, and lung damage by inducing 2,3-BPG production and triggering O 2 release in an AMPK-dependent manner ( Figure 6I ). Erythrocyte 2,3-BPG levels are increased by high-altitude hypoxia in normal individuals 15 and in patients with cardiovascular disease frequently facing hypoxia. [17] [18] [19] Here, we found that adenosine is induced by high altitude and that our newly identified erythrocyte adenosine signaling cascade promotes O 2 delivery to prevent tissue hypoxia. Thus, our findings are highly significant and highlight multiple new therapeutic avenues to prevent and treat hypoxia-induced tissue injury in both normal individuals at high altitude and patients with cardiovascular disease facing hypoxia.
Although extracellular adenosine is known to be induced under hypoxia, no prior study has reported that plasma adenosine levels are increased at high altitude, and a role for elevated plasma adenosine in high-altitude adaptation has never been recognized before our study with young healthy human volunteers. Here, we show for the first time that plasma adenosine levels were induced at ALT1 and increased further at ALT16. Consistent with the high altitude-dependent increase in plasma adenosine, we also found that the activity of sCD73, likely released from endothelial cells, was significantly induced by high-altitude hypoxia. Moreover, we confirmed early studies showing that erythrocyte 2,3-BPG and O 2 releasing capacity were significantly elevated in humans at high altitude. The elevated plasma adenosine concentration is associated with increased erythrocyte 2,3-BPG concentration and O 2 releasing capacity. Similar to humans at high altitude, we found that sCD73 activity, plasma adenosine level, erythrocyte 2,3-BPG concentration, and O 2 release capacity were significantly elevated in WT mice under hypoxia (10% O 2 ) for 1 week. However, genetic deletion of CD73 significantly reduced hypoxia-induced plasma adenosine, erythrocyte 2,3-BPG, and O 2 releasing capacity in mice. The decreased O 2 availability to peripheral tissues resulted in multiple tissue hypoxia, enhanced inflammation, and pulmonary damage, which is consistent with early studies showing that genetic deletion of CD73 leads to vascular leakage and increased immune cell infiltration in the lungs under hypoxia. 27, 44 Erythrocyte-specific ADORA2B knockouts allowed us to demonstrate for the first time that ADORA2B is essential for elevated plasma adenosine-induced-2,3-BPG production and O 2 releasing capacity from erythrocytes. The ablation of erythrocyte ADORA2B in mice resulted in severe tissue hypoxia, inflammation, and lung injury, similar to CD73-deficient mice. Thus, we have determined that elevated plasma adenosine signaling via erythrocyte ADORA2B plays an important role in preventing multiple tissue hypoxia and injury by inducing erythrocyte 2,3-BPG concentration and triggering O 2 release to local tissues. The discovery of this adenosine-activated erythrocyte signaling pathway reveals new dimensions of the importance of adenosine signaling in adaptation to hypoxia and immediately suggests novel therapeutics to counteract tissue hypoxia in normal individuals at high altitude and patients with cardiovascular disease frequently suffering from hypoxia.
AMPK is a well-known metabolic stress-sensing kinase that plays an essential role in regulating cellular energy metabolism. 45, 46 In erythrocytes, AMPK plays critical roles in regulating oxidative stress and maintaining the integrity and life span of the cell. [47] [48] [49] [50] A previous study used a proteomics approach to identify 2,3-BPG mutase as a potential AMPK target in erythrocytes. 35 Our present work revealed that AMPK, functioning downstream of ADORA2B, phosphorylates and activates 2,3-BPG mutase, resulting in increased 2,3-BPG production and elevated O 2 release from erythrocytes. Moreover, we showed that AICAR induced phosphorylation of AMPK and the activation of 2,3-BPG mutase, 2,3-BPG production, and O 2 release capacity in cultured WT mouse erythrocytes. In contrast, the AMPK inhibitor Compound C significantly attenuated the effects of AICAR in cultured WT mouse erythrocytes. Because of the importance of AMPK in inducing 2,3-BPG production in erythrocytes and the broad use of AICAR as an AMPK activator previously, 18 we conducted preclinical studies and found that pretreatment with AICAR induced erythrocyte 2,3-BPG concentration and O 2 availability to local tissue in both Cd73 −/− mice and Adora2b f/f /EpoR-Cre + mice under hypoxia. Furthermore, we demonstrated that AICAR enhanced hypoxia adaptation by rapidly inducing erythrocyte AMPK phosphorylation, 2,3-BPG mutase activity, and 2,3-BPG levels and triggering O 2 release to local tissue in WT mice. Similar to mouse findings, we showed that p-AMPK and 2,3-BPG mutase activity were significantly elevated in erythrocytes of humans facing high-altitude hypoxia. The significance of our mouse finding is further supported by human translational studies showing that AICAR-induced p-AMPK, 2,3-BPG mutase activity, 2,3-BPG production, and O 2 releasing capacity in cultured normal human erythrocytes. In contrast, Compound C attenuates AICAR-induced p-AMPK, 2,3-BPG mutase activation, 2,3-BPG production, and O 2 releasing capacity in cultured normal human erythrocytes. Thus, preclinical studies in mice and translational studies with human volunteers provide a strong foundation for future clinical trials in humans to test the ability of AMPK activators to increase O 2 availability in humans adapting to high altitude or facing other hypoxia challenges ( Figure 6I ).
cOnclusiOns
We have identified a functional role of CD73-dependent elevated extracellular adenosine signaling in O 2 release from hemoglobin in erythrocytes in response to hypoxia. This discovery has revealed a previously unrecognized role of adenosine signaling in erythrocyte physiology and provides a novel molecular mechanism underlying adaptation to hypoxia. Moreover, our finding that AMPK, functioning downstream of ADORA2B in erythrocytes, activates 2,3-BPG mutase and subsequently induces 2,3-BPG production and O 2 releasing capacity has important clinical implications. Overall, our present studies have added significant insight into the molecular mechanisms underlying human adaptation to hypoxia to counteract tissue hypoxia, inflammation, and injury and thereby have highlighted novel therapeutic possibilities for prevention and treatment of hypoxia-related conditions and diseases. Figure 6 continued. group vs 2-hour group and for AICAR-treated 4-hour group vs DMSO-treated 4-hour group; #P<0.05 for AICAR plus Compound C vs AICAR at the same time point (n=8). i, Working model: CD73 is essential for high-altitude hypoxiainduced plasma adenosine production. Elevated plasma adenosine prevents hypoxia-induced tissue inflammation and damage by activating A2B adenosine receptor (ADORA2B) on erythrocytes to induce 2,3-BPG mutase activity, 2,3-BPG production, and subsequently increased P50 and increased O 2 release to peripheral hypoxic tissues. AMPK is a key enzyme that functions downstream of ADORA2B to activate 2,3-BPG mutase and to promote 2,3-BPG production and O 2 release from erythrocytes. Thus, enhancing the CD73-ADORA2B-AMPK signaling pathway is a promising therapeutic strategy to treat or prevent hypoxia-induced tissue damage. IB indicates immunoblot; IP, immunoprecipitation; and sCD73, soluble CD73.
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